YS Biopharma (NASDAQ:YS – Get Rating) is one of 721 public companies in the “Holding & other investment offices” industry, but how does it contrast to its competitors? We will compare YS Biopharma to related companies based on the strength of its valuation, dividends, profitability, analyst recommendations, earnings, risk and institutional ownership.
Volatility & Risk
YS Biopharma has a beta of -0.48, indicating that its stock price is 148% less volatile than the S&P 500. Comparatively, YS Biopharma’s competitors have a beta of 0.04, indicating that their average stock price is 96% less volatile than the S&P 500.
Valuation & Earnings
This table compares YS Biopharma and its competitors gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| YS Biopharma | N/A | -$550,000.00 | 1.98 |
| YS Biopharma Competitors | $1.36 billion | -$8.27 million | -8.38 |
Profitability
This table compares YS Biopharma and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| YS Biopharma | N/A | 46.53% | 8.78% |
| YS Biopharma Competitors | -48.76% | -66.88% | -1.61% |
Institutional & Insider Ownership
46.0% of YS Biopharma shares are held by institutional investors. Comparatively, 66.5% of shares of all “Holding & other investment offices” companies are held by institutional investors. 18.3% of shares of all “Holding & other investment offices” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings for YS Biopharma and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| YS Biopharma | 0 | 0 | 0 | 0 | N/A |
| YS Biopharma Competitors | 115 | 593 | 885 | 15 | 2.50 |
As a group, “Holding & other investment offices” companies have a potential upside of 250.50%. Given YS Biopharma’s competitors higher possible upside, analysts clearly believe YS Biopharma has less favorable growth aspects than its competitors.
About YS Biopharma
YS Biopharma Co. Ltd. is a biopharmaceutical company. It focuses on discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company operates principally in China, the United States, Singapore, the United Arab Emirates and the Philippines. YS Biopharma Co. Ltd., formerly known as Summit Healthcare Acquisition Corp., is based in NEW YORK.
Receive News & Ratings for YS Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for YS Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
